Bristol-Myers Squibb Company (ETR:BRM)
Germany
· Delayed Price · Currency is EUR | Market Cap | 91.26B |
| Revenue (ttm) | 40.94B |
| Net Income (ttm) | 5.15B |
| Shares Out | n/a |
| EPS (ttm) | 2.53 |
| PE Ratio | 17.73 |
| Forward PE | 8.22 |
| Dividend | 2.22 (4.93%) |
| Ex-Dividend Date | Oct 3, 2025 |
| Volume | 4,563 |
| Average Volume | 4,123 |
| Open | 44.71 |
| Previous Close | 44.41 |
| Day's Range | 44.48 - 45.07 |
| 52-Week Range | 36.60 - 58.79 |
| Beta | 0.31 |
| RSI | 72.62 |
| Earnings Date | Feb 5, 2026 |
About ETR:BRM
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
News
Bristol Myers' Cancer Breakthrough Breyanzi Just Won Its Fifth FDA Approval
On Thursday, the U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb & Co.’s (NYSE: BMY) Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CA...
FDA Approves Bristol Myers' Breyanzi For Relapsed/Refractory Marginal Zone Lymphoma
(RTTNews) - Bristol Myers Squibb (BMY) today announced that the FDA has expanded Breyanzi's approval to include treatment of relapsed or refractory (R/R) marginal zone lymphoma in adult patients who h...
FDA Approves Bristol Myers Squibb's Breyanzi As First CAR T Therapy For R/R Marginal Zone Lymphoma
(RTTNews) - Bristol Myers Squibb (BMY) announced that the U.S. Food and Drug Administration has approved Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) ...
Bristol Myers (BMY) Receives FDA Approval for New Cancer Therapy
Bristol Myers (BMY) Receives FDA Approval for New Cancer Therapy
Bristol-Myers Squibb Company (BMY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Bristol-Myers Squibb Co at Citi Global Healthcare Conference Transcript
Bristol-Myers Squibb Co at Citi Global Healthcare Conference Transcript
BMY Gains on News of Continuation of Alzheimer's Disease Study
Bristol Myers jumps after choosing to continue its phase III ADEPT-2 study on Cobenfy for Alzheimer-related psychosis, delaying data to next year.
Bristol Myers (BMY) to Expand ADEPT-2 Study Enrollment
Bristol Myers (BMY) to Expand ADEPT-2 Study Enrollment
What's Going On With Bristol-Myers Squibb Shares Wednesday?
Bristol-Myers Squibb Company (NYSE: BMY) shares are trading higher Wednesday after the company announced that it will enroll additional patients in the ADEPT-2 study . What To Know: Bristol Myers sai...
A delayed clinical trial actually boosted Bristol Myers Squibb’s stock. Here’s why.
Bristol Myers’ stock rallied Wednesday as investors maintained high hopes for Cobenfy as an Alzheimer’s treatment, even though the outcome of a late-stage trial has been delayed.
Bristol Myers Pushes Data Readout For Key Alzheimer's Psychosis Study After Irregularities
Bristol Myers Squibb & Co . (NYSE: BMY) on Wednesday said it would enroll additional patients in the ADEPT-2 Phase 3 study . BMY shares are climbing with conviction. See the market dynamics here. The...
Bristol Myers Squibb (BMY) Delays Alzheimer's Drug Trial Results
Bristol Myers Squibb (BMY) Delays Alzheimer's Drug Trial Results
Bristol Myers (BMY) Advances in Alzheimer's Study Facing Trial Challenges
Bristol Myers (BMY) Advances in Alzheimer's Study Facing Trial Challenges
Bristol Myers (BMY) Bolsters ADEPT-2 Alzheimer's Study with More Participants
Bristol Myers (BMY) Bolsters ADEPT-2 Alzheimer's Study with More Participants
Why A Surprise Delay For Cobenfy Just Sparked Bristol Myers Stock
Bristol Myers Squibb stock popped Wednesday after the firm delayed a study testing Cobenfy in Alzheimer's disease psychosis.
Bristol Myers To Enroll Addl. Patients In Phase 3 ADEPT-2 Study Following Regulatory Consultations
(RTTNews) - Bristol Myers Squibb (BMY) announced Wednesday that it agrees with the decision made in consultation with the U.S. Food and Drug Administration (FDA) and Data Monitoring Committee (DMC) to...
Bristol Myers (BMY) Expands ADEPT-2 Study to Address Irregularities
Bristol Myers (BMY) Expands ADEPT-2 Study to Address Irregularities
BMY: Goldman Sachs Raises Bristol-Myers Squibb Price Target to $57 | BMY Stock News
BMY: Goldman Sachs Raises Bristol-Myers Squibb Price Target to $57 | BMY Stock News
Bristol Myers Squibb (BMY) Faces $6.7 Billion Lawsuit Over Celgene Deal
Bristol Myers Squibb (BMY) Faces $6.7 Billion Lawsuit Over Celgene Deal
US judge rules Bristol Myers faces $6.7B lawsuit over delayed cancer drug - report
Bristol Myers Squibb Unveils Positive Trial Data In Hematology Pipeline
(RTTNews) - Drug maker Bristol Myers Squibb Co. (BMY) announced Monday positive and promising data from the trials in Hematology pipeline, comprising Iberdomide, Golcadomide, BCL6 Degrader, as well as...
Bristol Myers (BMY) Showcases Breakthroughs in Hematology at ASH Meeting
Bristol Myers (BMY) Showcases Breakthroughs in Hematology at ASH Meeting
Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of more than 95 data disclosures, including 27 oral presentations, across company-sponsored studies and external collaborations at the...
Should You Buy Bristol Myers Stock for Its 5.4%-Yielding Dividend?
The pharma stock yields more than 4x the S&P 500 average.
Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?
GILD's HIV strength, new approvals, and rising estimates set it apart as it edges past a challenged rival in growth prospects.